Post-merg­er, gene ther­a­py play­er Ad­verum makes Am­ber Salz­man CEO, de­lays a clin­i­cal tri­al start

Avalanche Biotech­nolo­gies’ ac­qui­si­tion of Paris-based An­na­pur­na and their merg­er in­to a new gene ther­a­py com­pa­ny called Ad­verum Biotech­nolo­gies $AD­VM is still play­ing out.

Five months …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER